RU2019115946A - Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 - Google Patents

Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 Download PDF

Info

Publication number
RU2019115946A
RU2019115946A RU2019115946A RU2019115946A RU2019115946A RU 2019115946 A RU2019115946 A RU 2019115946A RU 2019115946 A RU2019115946 A RU 2019115946A RU 2019115946 A RU2019115946 A RU 2019115946A RU 2019115946 A RU2019115946 A RU 2019115946A
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
lcvr
hcvr
Prior art date
Application number
RU2019115946A
Other languages
English (en)
Russian (ru)
Other versions
RU2019115946A3 (https=
Inventor
Майкл Х. КЕЙГИ
Синтия А. СИРАРД
Original Assignee
Лип Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лип Терапьютикс, Инк. filed Critical Лип Терапьютикс, Инк.
Publication of RU2019115946A publication Critical patent/RU2019115946A/ru
Publication of RU2019115946A3 publication Critical patent/RU2019115946A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019115946A 2016-10-26 2017-10-26 Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 RU2019115946A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413198P 2016-10-26 2016-10-26
US62/413,198 2016-10-26
PCT/US2017/058555 WO2018081437A1 (en) 2016-10-26 2017-10-26 Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Publications (2)

Publication Number Publication Date
RU2019115946A true RU2019115946A (ru) 2020-11-27
RU2019115946A3 RU2019115946A3 (https=) 2021-01-26

Family

ID=60570180

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019115946A RU2019115946A (ru) 2016-10-26 2017-10-26 Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1

Country Status (14)

Country Link
US (2) US11267876B2 (https=)
EP (1) EP3532099A1 (https=)
JP (2) JP7374765B2 (https=)
KR (1) KR102701695B1 (https=)
CN (1) CN110114087A (https=)
AU (1) AU2017347822B2 (https=)
BR (1) BR112019008279A2 (https=)
CA (1) CA3041325A1 (https=)
IL (1) IL266199B2 (https=)
MA (1) MA46673A (https=)
MX (1) MX2019004940A (https=)
RU (1) RU2019115946A (https=)
SG (1) SG11201903602RA (https=)
WO (1) WO2018081437A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041325A1 (en) 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
CA3128526A1 (en) 2019-02-01 2020-08-06 Board Of Regents, The University Of Texas System Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof
CA3151228A1 (en) * 2019-09-19 2021-03-25 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
EP4061419A1 (en) * 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
WO2023143444A1 (zh) 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途
US20250222062A1 (en) * 2022-03-24 2025-07-10 The Translational Genomics Research Institute Peptide inhibitors targeting the tbl1-beta-catenin complex
CN116350758B (zh) * 2023-03-16 2024-08-06 郑州大学 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CA2677356A1 (en) 2007-02-08 2008-08-14 Zhiqiang An Antibodies specific for dkk-1
WO2009028158A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
EP2427490A1 (en) 2009-05-07 2012-03-14 Novartis AG Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012103787A1 (en) * 2011-02-01 2012-08-09 The University Of Hongkong Use of anti-dkk1 monoclonal antibody for treatment of liver cancer
JP6465790B2 (ja) * 2013-02-27 2019-02-06 第一三共株式会社 Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
CA2931975A1 (en) 2013-12-02 2015-06-11 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
CA3041325A1 (en) 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
CA3151228A1 (en) 2019-09-19 2021-03-25 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
EP4061419A1 (en) 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
IL318268A (en) 2022-07-12 2025-03-01 Leap Therapeutics Inc Combined treatment

Also Published As

Publication number Publication date
US11267876B2 (en) 2022-03-08
CA3041325A1 (en) 2018-05-03
MX2019004940A (es) 2019-09-26
SG11201903602RA (en) 2019-05-30
BR112019008279A2 (pt) 2019-07-09
AU2017347822A1 (en) 2019-05-09
IL266199B1 (en) 2024-10-01
IL266199B2 (en) 2025-02-01
AU2017347822B2 (en) 2025-01-16
US20190284264A1 (en) 2019-09-19
CN110114087A (zh) 2019-08-09
KR20190085935A (ko) 2019-07-19
US12319730B2 (en) 2025-06-03
KR102701695B1 (ko) 2024-08-30
US20220289831A1 (en) 2022-09-15
JP7374765B2 (ja) 2023-11-07
JP2019533693A (ja) 2019-11-21
MA46673A (fr) 2019-09-04
JP2023133432A (ja) 2023-09-22
EP3532099A1 (en) 2019-09-04
IL266199A (en) 2019-06-30
RU2019115946A3 (https=) 2021-01-26
WO2018081437A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
RU2019115946A (ru) Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1
JP2023133432A5 (https=)
RU2015127089A (ru) Композиции, содержащие антитела к cd38 и леналидомид
JP2021527431A5 (https=)
RU2014108047A (ru) Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
JP2021524244A5 (https=)
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
RU2018108048A (ru) Новые анти-pd-1 антитела
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
JP2019526622A5 (https=)
HRP20200745T1 (hr) Agensi koji vezuju cd123 i njihove upotrebe
JP2015535828A5 (https=)
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
RU2017114341A (ru) Антитела к pd-l1, связывающие pd-l1 собаки
RU2020129387A (ru) Антитела к pd-1 собак
RU2010107175A (ru) Антитела человека к cd20 человека и способ их использования
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
RU2009117237A (ru) Средство для профилактики/лечения рака
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
JP2021500916A5 (https=)
RU2013138177A (ru) Антитела, действующие селективно на клетки с повышенной плотностью мишени рецептор эпидермального фактора роста (egfr)
RU2015143462A (ru) Композиции, включающие антитела к cd38 и карфилзомиб
RU2016137256A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb